Genetic panel aims to spot heart risk before cancer therapy begins
NCT ID NCT07663357
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a genetic and epigenetic panel can predict heart damage caused by chemotherapy or immunotherapy in breast cancer patients. Researchers will analyze blood samples from 1,000 participants before and during treatment to see if certain genetic markers signal early risk. The goal is to catch potential heart problems sooner, allowing doctors to adjust treatment and protect patients' hearts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pharmacogenomic panel
What this could lead to
If successful, this could enable doctors to identify patients at high risk for heart damage before starting cancer treatment, allowing for safer, personalized therapy.
What could go wrong
This is an observational study, not a treatment trial. The genetic panel may not accurately predict cardiotoxicity in all patients, and results may not change outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complexo Hospitar HUOC/PROCAPE
NOT_YET_RECRUITINGRecife, Pernambuco, 50100-130, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
FAMERP - Faculdade de Medicina de São José do Rio Preto
NOT_YET_RECRUITINGSão José do Rio Preto, São Paulo, 15090-000, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital BP - A Beneficência Portuguesa de São Paulo
RECRUITINGSão Paulo, São Paulo, 01323-900, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Beneficente UNIMAR
NOT_YET_RECRUITINGMarília, São Paulo, 17525-160, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto do Câncer do Ceará
NOT_YET_RECRUITINGFortaleza, Ceará, 60430-230, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universidade Federal de Santa Catarina
NOT_YET_RECRUITINGFlorianópolis, Santa Catarina, 88040-900, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••